Sanofi becomes latest drugmaker to challenge HHS over 340B drug-discount program

by
Contributor since / Followers

1 month ago

Following in the footsteps of Johnson & Johnson (JNJ) and Eli Lilly (LLY), Sanofi (NASDAQ:SNY) has become the latest pharma challenging HHS’ 340B program that provides discounted drugs to hospitals and clinics that primarily serve poor and underinsured patients.
Although

Tags: JNJ